View Older Stories

Apr 13, 2026 03:07PM William Blair stays Outperform on Ocular Therapeutix (OCUL) following Axpaxli data

Mar 27, 2026 06:47AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)

Mar 24, 2026 04:23AM Ocular Therapeutix (OCUL) Reiterated at Market Outperform by Citizens Amid Litigation

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 2, 2026 04:01PM Ocular Therapeutix (OCUL) PT Raised to $28 at Clear Street

Mar 2, 2026 10:19AM William Blair Reiterates Outperform Rating on Ocular Therapeutix (OCUL) following study results

Feb 20, 2026 07:53AM Ocular Therapeutix (OCUL) PT Lowered to $18 at Needham

Feb 19, 2026 02:01PM FDA policy 'suportive' of Ocular Therapeutix (OCUL) Axpaxli NDA Submission on SOL-1 Alon - Raymond James

Feb 19, 2026 10:41AM Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 5, 2026 08:55AM RBC Capital on Ocular Therapeutix (OCUL): Weakness a Buying Opportunity

Feb 5, 2026 07:43AM Ocular Therapeutix (OCUL) Tops Q4 EPS by 3c

Jan 15, 2026 10:01AM Ocular Therapeutix jumps on report Sanofi preparing revised bid

Jan 13, 2026 04:59AM Increasing unusual put option volume: SCCO OCUL SLS CSGP BAX EQNR VNET MXEF CMBT SYF

Dec 18, 2025 06:24AM BofA: 'Top SMid Biotech Picks Argenx, KalVista, Ocular, and Vertex'

Dec 17, 2025 10:43AM Increasing unusual put option volume: JBL AIG CB IRBT XP LOGI SOXX UDOW LIN LEN NICE CPNG

Dec 16, 2025 08:38AM TD Cowen on Ocular Therapeutix (OCUL): 'Great Data Could Lead To 45% Upside Per Investor Survey'

Dec 16, 2025 04:21AM Ocular (OCUL) Reiterated at Market Outperform by Citizens

Dec 9, 2025 04:00AM Ocular Therapeutix (OCUL) PT Raised to $30 at RBC Capital

Dec 8, 2025 07:02AM Ocular Therapeutix plans to accelerate AXPAXLI submission for wet AMD

Dec 8, 2025 06:46AM Ocular Therapeutix (OCUL) PT Raised to $21 at H.C. Wainwright

Dec 8, 2025 05:08AM Ocular Therapeutix (OCUL) PT Raised to $28 at Raymond James

Dec 8, 2025 04:34AM Ocular Therapeutix's (OCUL) SOL-1 Trial Could Lead to Approval - Citizens

Nov 5, 2025 10:02AM Ocular Therapeutix (OCUL) PT Raised at RBC Capital; 'DR May Offer Additional Upside Potential'

Nov 4, 2025 07:12AM Ocular Therapeutix (OCUL) Misses Q3 EPS by 1c

Nov 4, 2025 07:02AM Ocular Therapeutix completes enrollment in wet AMD drug trial

Oct 30, 2025 09:38AM Ocular Therapeutix (OCUL) PT Raised to $20 at TD Cowen

Oct 8, 2025 06:45AM Ocular Therapeutix (OCUL) PT Raised to $19 at H.C. Wainwright

Oct 3, 2025 08:19AM Ocular Therapeutix (OCUL) PT Raised to $31 at Piper Sandler

Oct 1, 2025 04:29AM Ocular Therapeutix (OCUL) PT Raised to $29 at Citizens JMP

Sep 30, 2025 06:21AM Ocular Therapeutix hosts investor day detailing AXPAXLI trial progress

Sep 30, 2025 06:15AM Ocular Therapeutix (OCUL) files mixed shelf

Sep 15, 2025 05:07AM Chardan Capital Markets Starts Ocular Therapeutix (OCUL) at Buy

Aug 12, 2025 07:01AM Ocular Therapeutix gets FDA agreement for AXPAXLI diabetic eye trial

Aug 5, 2025 12:45PM TD Cowen on Ocular Therapeutix (OCUL): 'SOL-1 Data In Q1:2026 Should Be Positive And Clinically Relevant'

Aug 5, 2025 11:11AM Clear Street Reiterates Buy Rating on Ocular Therapeutix (OCUL)

Aug 5, 2025 11:07AM Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)

Aug 5, 2025 07:13AM Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c

Aug 4, 2025 01:18PM Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)

May 30, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)

May 28, 2025 03:47PM Clear Street Reiterates Buy Rating on Ocular Therapeutix (OCUL) Following Quick SOL-R Enrollment Completion

May 5, 2025 09:48AM Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)

May 5, 2025 07:04AM Ocular Therapeutix (OCUL) Misses Q1 EPS by 9c

Apr 23, 2025 04:22AM Citizens JMP Reiterates Market Outperform Rating on Ocular Therapeutix (OCUL)

Apr 8, 2025 07:59AM William Blair Starts Ocular Therapeutix (OCUL) at Outperform, 'we believe Axpaxli has the potential to show best-in-class efficacy and durability'

Mar 26, 2025 06:55AM Ocular Therapeutix (OCUL) Raymond James Adjusts Analyst Current Favorites List

Mar 7, 2025 04:08PM Ocular Therapeutix (OCUL) announce inducement grants to new employee

Mar 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)

Mar 4, 2025 04:29AM Ocular Therapeutix (OCUL) PT Lowered to $19 at Citizens JMP

Mar 3, 2025 11:48AM Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17

Mar 3, 2025 11:47AM Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL), PT $19

View Older Stories